Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Ocean Biomedical, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 8-K Quarterly results
10/06/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "FIRST AMENDMENT TO COMMON STOCK PURCHASE AGREEMENT, DATED",
"Ocean Biomedical Announces Loan Commitment from Largest"
10/02/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "SIDE LETTER"
06/08/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "AMENDMENT TO LOAN AGREEMENT, DATED JUNE 2, 2023",
"OMNIBUS AMENDMENT TO LOAN AGREEMENTS, DATED JUNE 2, 2023"
05/26/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT"
05/16/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "[FORM OF SENIOR SECURED CONVERTIBLE NOTE] NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL TO THE HOLDER , IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE ...",
"[FORM OF WARRANT] NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL TO THE HOLDER , IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER ...",
"GUARANTY This GUARANTY, dated as of May 16, 2023 , is made by each of the undersigned , in favor of Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B, in its capacity as collateral agent for the “Buyers” party to the Securities Purchase Agreement . W I T N E S S E T H : WHEREAS, Ocean Biomedical, Inc., a company organized under the laws of Delaware, with offices located at 55 Claverick St. Rm. 325, Providence, RI 02903 and each party listed as a “Buyer” on the Schedule of Buyers attached thereto are parties to the Securities Purchase Agreement, dated as of May 15, 2023 , pursuant to which the Company shall be required to sell, and the Buyers shall purchase or have the right to purchase, the “Notes” issued pursuant thereto ; WHEREAS, the Securities Purchase Agreement require...",
"W I T N E S S E T H : WHEREAS, the Company is party to that certain Securities Purchase Agreement, dated as of May 15, 2023, by and among the Company and each party listed as a “Buyer” on the Schedule of Buyers attached thereto , pursuant to which the Company shall be required to sell, and the Buyers shall purchase or have the right to purchase, the “Notes” issued pursuant thereto ; WHEREAS, certain Grantors from time to time may execute and deliver one or more guarantees in form and substance acceptable to and in favor of the Collateral Agent, for the ratable benefit of itself and the Noteholders, with respect to the Company’ s obligations under the Securities Purchase Agreement, the Notes and the other Transaction Documents",
"RECITALS",
"RECITALS",
"Ocean Biomedical, Inc. Enters into a $25 Million Convertible Note Facility"
03/17/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
02/13/2023 8-K Quarterly results
02/13/2023 8-K Quarterly results
02/10/2023 8-K Quarterly results
02/09/2023 8-K Quarterly results
02/08/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
02/07/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
02/06/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact"
02/01/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aesther Healthcare Acquisition Corp Announces Measures regarding Excise Tax NEWS PROVIDED BY Aesther Healthcare Acquisition Corp February 1, 2023, [●] ET NEW YORK and PROVIDENCE, R.I., February 1, 2023 — Aesther Healthcare Acquisition Corp , a special purpose acquisition company and Ocean Biomedical, Inc. , a next-generation biopharma company announced today that AEHA has filed with the U.S. Securities and Exchange Commission a definitive proxy statement in connection with its proposed business combination with Ocean and with respect to the special meeting of Aesther’ s stockholders scheduled to be held on February 3, 2023. Aesther and Ocean are issuing this press release to notify all concerned parties regarding Aesther and Ocean’ s commitment to retain sufficient funds in its Trust..."
01/30/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Ocean Biomedical, Inc."
01/24/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact"
01/13/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aesther Healthcare Acquisition Corp Announces Filing of Definitive Proxy Statement with SEC in Connection with its Proposed Business Combination with Ocean Biomedical, Inc. NEWS PROVIDED BY Aesther Healthcare Acquisition Corp January 13, 2023, [●] ET NEW YORK and PROVIDENCE, R.I., Jan. 13, 2023 — Aesther Healthcare Acquisition Corp , a special purpose acquisition company and Ocean Biomedical, Inc. , a next-generation biopharma company announced today that AEHA has filed with the U.S. Securities and Exchange Commission a definitive proxy statement in connection with its proposed business combination with Ocean and with respect to the special meeting of Aesther’ s stockholders scheduled to be held on February 3, 2023. The proposed Transaction was unanimously approved by the boards of d..."
12/16/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aesther Healthcare Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Business Combination"
12/13/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aesther Healthcare Acquisition Corp. Announces Intention to Extend Period to Consummate Business Combination"
12/08/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "AMENDMENT TO AGREEMENT AND PLAN OF MERGER"
11/21/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Amendment to Forward Share Purchase Agreement, by and between the Company, Ocean Biomedical, and the Investors"
10/05/2022 8-K Quarterly results
09/22/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aesther Healthcare Acquisition Corp."
09/19/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aesther Healthcare Acquisition Corp Announces Filing of Preliminary Proxy Statement with SEC in Connection with its Proposed Business Combination with Ocean Biomedical, Inc. NEWS PROVIDED BY Aesther Healthcare Acquisition Corp September 19, 2022, 07:45 am ET NEW YORK and PROVIDENCE, R.I., Sept. 19, 2022 — Aesther Healthcare Acquisition Corp , a special purpose acquisition company and Ocean Biomedical, Inc. , a next-generation biopharma company announced today that AHEA has filed with the U.S. Securities and Exchange Commission a preliminary proxy statement in connection with its proposed business combination with Ocean. The combined company will work to accelerate the development of Ocean Biomedical’ s core assets in oncology, fibrosis, and infectious diseases, all based on new target disc..."
09/12/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aesther Healthcare Acquisition Corp. Announces Intention to Extend Period to Consummate Business Combination"
09/09/2022 8-K Quarterly results
09/08/2022 8-K Quarterly results
09/07/2022 8-K Quarterly results
09/06/2022 8-K Quarterly results
08/31/2022 8-K Quarterly results
07/19/2022 8-K Quarterly results
07/08/2022 8-K Quarterly results
06/02/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy